Recardio announces conclusion of interim analysis of Phase 2 in AMI – News.MarketSizeForecasters.com

Recardio announces conclusion of interim analysis of Phase 2 in AMI

Treatment trials across various pharmaceutical companies are on the go lately. Supporting the same, Recardio, one of the clinical stage life science companies, reportedly announced the completion of an interim analysis of its Phase 2 study of dutogliptin and filgrastim, combined, in early recovery post-myocardial infarction. Moreover, it has been estimated that the patient recruitment for the study is still continuing at all the participating centers of the company.

The placebo-controlled Phase 2 study is expected to enroll nearly 120 patients globally. Apparently, the study is planned to evaluate the efficiency and safety of the companys dutogliptin, which is used to restore the dropped myocardial function in patients experiencing severe heart attack and percutaneous coronary intervention.

Further, the analysis was carried out in agreement with the analysis Data Safety Monitoring Board, which produced an authentication of the study and its continuation, prompting participating trial centers to carry on their patient recruitment operations, globally.

Speaking on the completion of the analysis, Recardios Executive Chairman, Roman Schenk reportedly quoted that the interim analysis has been a crucial milestone for completion of the study. The company is highly encouraged by the efforts of several clinical investigators and is determined to conclude the trial by this year end.

It has been reported that Recardios regenerative therapeutic approach to reduce and repair heart muscle injury constitutes recruiting, mobilizing, and homing stem cells in-vivo by making use of cytokines and inhibitors.

Headquartered in California, Recardio Inc., is a clinical stage life science company which focuses on therapies involving the cardiovascular, oncology, and infectious disorders. The companys lead drug, dutogliptin has demonstrated considerable effects in activating vivid chemokines essential for treatment of different cardiovascular diseases.

Source credits: https://recardio.eu/2020/02/recardio-completes-interim-analysis-of-phase-2-in-ami/

Visit link:
Recardio announces conclusion of interim analysis of Phase 2 in AMI - News.MarketSizeForecasters.com